盐酸埃克替尼治疗EGFR突变阳性非小细胞肺癌脑转移的近期效果分析

Short term effect of icotinib hydrochloride in treatment of EGFR mutation positive brain metastases from non-small cell lung cancer

目的 探究盐酸埃克替尼对表皮生长因子受体(EGFR)突变阳性非小细胞肺癌脑转移的近期效果.方法 选取于南阳市中心医院肿瘤医院收治的EGFR突变阳性非小细胞肺癌脑转移患者共60例,所有患者均接受盐酸埃克替尼片口服治疗,125 mg/次,3次/d.回顾性分析其近期效果.结果 患者中位无进展生存期为12.6个月(95%CI 11.85~14.42).所有患者均接受疗效评估,其中部分缓解(PR) 23例,稳定(SD) 37例,EGFR突变非小细胞肺癌(NSCLC)脑转移患者的有效率(ORR)为38.33%,疾病控制率(DCR)为100%.患者的治疗史、基因突变情况、性别以及吸烟与否与治疗无进展生存期(PFS)均无显著相关性(P>0.05);患者的治疗史,性别与是否吸烟与ORR无显著相关性(P>0.05),而患者的基因突变情况与ORR显著相关(P<0.05).不良反应发生情况:皮疹共出现5例,皮肤干燥9例,腹泻3例,肝功能异常2例.结论 盐酸埃克替尼治疗EGFR突变阳性非小细胞肺癌脑转移疗效显著,临床应用前景光明.

Objective To explore the short-term effect of icotinib hydrochloride on EGFR mutation positive brain metastases from non-small cell lung cancer.Methods A total of 60 patients with brain metastasis from non-small cell lung cancer with EGFR mutation positive in Nanyang Central Hospital,Oncology Hospital were selected.All patients were treated with Icotinib Hydrochloride Tablets,125 mg/time,orally,three times daily.Retrospective analysis of its short-term effect.Results The median PFS was 12.6 months(95%CI 11.85 to 14.42).All patients were evaluated for efficacy with 23 cases of PR and 37 cases of SD.The treatment of ORR in NSCLC were 38.33%,and DCR were 100%.There was no significant correlation between the history of treatment,gene mutation,sex and smoking history with PFS(P> 0.05).There was no significant correlation between the history of treatment,sex,gender and whether smoking with ORR(P> 0.05),and the gene mutation of patients was significantly correlated with ORR(P <0.05).Adverse reactions occurred in 5 cases of rash,9 cases of skin drying,3 cases of diarrhea,and 2 cases of abnormal liver function.Conclusion Icotinib hydrochloride treatment of EGFR mutation positive brain metastases of NSCLC has significant effect,with promising clinical application.